The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma

Gynecologic Oncology

Volumn 70, Issue 1, 1998, Pages 131-133

  Letterie, Gerard S ^a   Yon, Joseph L ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Antiestrogen therapy; Cystic mesothelioma; Peritoneal inclusion cysts; Tamoxifen

Indexed keywords

TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; HUMAN; MESOTHELIOMA; OVARY CYST; PRIORITY JOURNAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

EID: 0032125829     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5031     Document Type: Article

References (4)

1. Fisher B, Constantino J P, Redmond C K, Fisher E R, Wickerham D L, Cronin W M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 86:1994;527-530.
2. Love R R, Mazess R B, Barden H S, Epstein S, Newcomb P A, Jordan V C, Carbone P P, De Mets D L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 36:1992;852-857.
3. Shirey D R, Kavangh J J, Gershenson D M, Freedman R S, Copeland L J, Jones L A. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol. 66:1985;575-578.
4. Letterie G S, Yon J L. Use of a long-acting GnRH agonist for benign cystic mesothelioma. Obstet Gynecol. 85:1995;901-903.